Effects of ipriflavone on bone mass and calcium metabolism in postmenopausal osteoporosis

D. Agnusdei, S. Adami, R. Cervetti, G. Crepaldi, O. Di Munno, L. Fantasia, G. C. Isaia, G. Letizia, S. Ortolani, M. Passeri, U. Serni, L. Vecchiet, C. Gennari

Research output: Contribution to journalArticle

Abstract

Recently it has been demonstrated that ipriflavone (IP), an isoflavone derivative, is able to increase bone mass in patients with established postmenopausal osteoporosis (PMO). Here we present a preliminary report of a 2-year multicenter, double-blind, placebo-controlled clinical study performed in order to evaluate the efficacy and tolerability of IP in PMO. A large number of patients with PMO, referred to 12 Italian centers, was randomly divided into 2 groups and treated with oral IP (600 mg/day) or placebo (PI). All patients received an oral Ca supplement (1 g/day). One hundred and twenty six patients completed 1 year of the study. Bone mineral density (BMD) of the distal radius, measured by DPA, serum osteocalcin (BGP), and urinary hydroxyproline excretion (HOP/Cr), were measured before and after 12 months. After 12 months, a significant increase in BMD was observed in the IP-treated group (P <0.05). IP determined a reduction of HOP/Cr, while in Pl-treated patients a significant increase of this index, as well as of BGP, was observed. After 12 months the difference between the two groups resulted significant (P <0.05) for BGP. The drug was well tolerated and the patients' compliance to the oral treatment resulted excellent. The results of this study indicate that IP is able to increase bone mass in patients with PMO.

Original languageEnglish
JournalBone and Mineral
Volume19
Issue numberSUPPL. 1
DOIs
Publication statusPublished - 1992

Fingerprint

Postmenopausal Osteoporosis
Metabolism
Bone
Calcium
Bone and Bones
Hydroxyproline
Bone Density
Minerals
Placebos
Isoflavones
Osteocalcin
Patient Compliance
ipriflavone
Serum
Pharmaceutical Preparations

Keywords

  • Ipriflavone
  • Postmenopausal osteoporosis

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology
  • Surgery

Cite this

Agnusdei, D., Adami, S., Cervetti, R., Crepaldi, G., Di Munno, O., Fantasia, L., ... Gennari, C. (1992). Effects of ipriflavone on bone mass and calcium metabolism in postmenopausal osteoporosis. Bone and Mineral, 19(SUPPL. 1). https://doi.org/10.1016/0169-6009(92)90865-B

Effects of ipriflavone on bone mass and calcium metabolism in postmenopausal osteoporosis. / Agnusdei, D.; Adami, S.; Cervetti, R.; Crepaldi, G.; Di Munno, O.; Fantasia, L.; Isaia, G. C.; Letizia, G.; Ortolani, S.; Passeri, M.; Serni, U.; Vecchiet, L.; Gennari, C.

In: Bone and Mineral, Vol. 19, No. SUPPL. 1, 1992.

Research output: Contribution to journalArticle

Agnusdei, D, Adami, S, Cervetti, R, Crepaldi, G, Di Munno, O, Fantasia, L, Isaia, GC, Letizia, G, Ortolani, S, Passeri, M, Serni, U, Vecchiet, L & Gennari, C 1992, 'Effects of ipriflavone on bone mass and calcium metabolism in postmenopausal osteoporosis', Bone and Mineral, vol. 19, no. SUPPL. 1. https://doi.org/10.1016/0169-6009(92)90865-B
Agnusdei, D. ; Adami, S. ; Cervetti, R. ; Crepaldi, G. ; Di Munno, O. ; Fantasia, L. ; Isaia, G. C. ; Letizia, G. ; Ortolani, S. ; Passeri, M. ; Serni, U. ; Vecchiet, L. ; Gennari, C. / Effects of ipriflavone on bone mass and calcium metabolism in postmenopausal osteoporosis. In: Bone and Mineral. 1992 ; Vol. 19, No. SUPPL. 1.
@article{b9342a56783b49f9b4d7124ce0992622,
title = "Effects of ipriflavone on bone mass and calcium metabolism in postmenopausal osteoporosis",
abstract = "Recently it has been demonstrated that ipriflavone (IP), an isoflavone derivative, is able to increase bone mass in patients with established postmenopausal osteoporosis (PMO). Here we present a preliminary report of a 2-year multicenter, double-blind, placebo-controlled clinical study performed in order to evaluate the efficacy and tolerability of IP in PMO. A large number of patients with PMO, referred to 12 Italian centers, was randomly divided into 2 groups and treated with oral IP (600 mg/day) or placebo (PI). All patients received an oral Ca supplement (1 g/day). One hundred and twenty six patients completed 1 year of the study. Bone mineral density (BMD) of the distal radius, measured by DPA, serum osteocalcin (BGP), and urinary hydroxyproline excretion (HOP/Cr), were measured before and after 12 months. After 12 months, a significant increase in BMD was observed in the IP-treated group (P <0.05). IP determined a reduction of HOP/Cr, while in Pl-treated patients a significant increase of this index, as well as of BGP, was observed. After 12 months the difference between the two groups resulted significant (P <0.05) for BGP. The drug was well tolerated and the patients' compliance to the oral treatment resulted excellent. The results of this study indicate that IP is able to increase bone mass in patients with PMO.",
keywords = "Ipriflavone, Postmenopausal osteoporosis",
author = "D. Agnusdei and S. Adami and R. Cervetti and G. Crepaldi and {Di Munno}, O. and L. Fantasia and Isaia, {G. C.} and G. Letizia and S. Ortolani and M. Passeri and U. Serni and L. Vecchiet and C. Gennari",
year = "1992",
doi = "10.1016/0169-6009(92)90865-B",
language = "English",
volume = "19",
journal = "Bone and Mineral",
issn = "0169-6009",
publisher = "Elsevier BV",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Effects of ipriflavone on bone mass and calcium metabolism in postmenopausal osteoporosis

AU - Agnusdei, D.

AU - Adami, S.

AU - Cervetti, R.

AU - Crepaldi, G.

AU - Di Munno, O.

AU - Fantasia, L.

AU - Isaia, G. C.

AU - Letizia, G.

AU - Ortolani, S.

AU - Passeri, M.

AU - Serni, U.

AU - Vecchiet, L.

AU - Gennari, C.

PY - 1992

Y1 - 1992

N2 - Recently it has been demonstrated that ipriflavone (IP), an isoflavone derivative, is able to increase bone mass in patients with established postmenopausal osteoporosis (PMO). Here we present a preliminary report of a 2-year multicenter, double-blind, placebo-controlled clinical study performed in order to evaluate the efficacy and tolerability of IP in PMO. A large number of patients with PMO, referred to 12 Italian centers, was randomly divided into 2 groups and treated with oral IP (600 mg/day) or placebo (PI). All patients received an oral Ca supplement (1 g/day). One hundred and twenty six patients completed 1 year of the study. Bone mineral density (BMD) of the distal radius, measured by DPA, serum osteocalcin (BGP), and urinary hydroxyproline excretion (HOP/Cr), were measured before and after 12 months. After 12 months, a significant increase in BMD was observed in the IP-treated group (P <0.05). IP determined a reduction of HOP/Cr, while in Pl-treated patients a significant increase of this index, as well as of BGP, was observed. After 12 months the difference between the two groups resulted significant (P <0.05) for BGP. The drug was well tolerated and the patients' compliance to the oral treatment resulted excellent. The results of this study indicate that IP is able to increase bone mass in patients with PMO.

AB - Recently it has been demonstrated that ipriflavone (IP), an isoflavone derivative, is able to increase bone mass in patients with established postmenopausal osteoporosis (PMO). Here we present a preliminary report of a 2-year multicenter, double-blind, placebo-controlled clinical study performed in order to evaluate the efficacy and tolerability of IP in PMO. A large number of patients with PMO, referred to 12 Italian centers, was randomly divided into 2 groups and treated with oral IP (600 mg/day) or placebo (PI). All patients received an oral Ca supplement (1 g/day). One hundred and twenty six patients completed 1 year of the study. Bone mineral density (BMD) of the distal radius, measured by DPA, serum osteocalcin (BGP), and urinary hydroxyproline excretion (HOP/Cr), were measured before and after 12 months. After 12 months, a significant increase in BMD was observed in the IP-treated group (P <0.05). IP determined a reduction of HOP/Cr, while in Pl-treated patients a significant increase of this index, as well as of BGP, was observed. After 12 months the difference between the two groups resulted significant (P <0.05) for BGP. The drug was well tolerated and the patients' compliance to the oral treatment resulted excellent. The results of this study indicate that IP is able to increase bone mass in patients with PMO.

KW - Ipriflavone

KW - Postmenopausal osteoporosis

UR - http://www.scopus.com/inward/record.url?scp=0026788553&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026788553&partnerID=8YFLogxK

U2 - 10.1016/0169-6009(92)90865-B

DO - 10.1016/0169-6009(92)90865-B

M3 - Article

C2 - 1422320

AN - SCOPUS:0026788553

VL - 19

JO - Bone and Mineral

JF - Bone and Mineral

SN - 0169-6009

IS - SUPPL. 1

ER -